Diabetes and Coronary Intervention: Special Considerations for Antithrombotic Therapy

R. Scott Wright1, Gregory W. Barsness

  • 1*Mayo Medical School, Division of Cardiology and The Mayo Physician Alliance for Clinical Trials, Mayo Clinic and Foundation, Stabile 5, 150 Third Street SW, Rochester, MN 55902, USA. wright.scott@mayo.edu

Current Interventional Cardiology Reports
|November 7, 2001
PubMed

Insights

Diabetic patients have advanced coronary artery disease and face unique challenges during percutaneous coronary intervention (PCI). Potent antithrombotic therapies improve PCI safety and effectiveness in this high-risk group.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes mellitus is a growing concern, linked to advanced coronary artery disease.
  • Diabetic patients present a prothrombotic state, complicating interventional cardiology procedures.
  • Percutaneous coronary intervention (PCI) in diabetics requires careful management due to increased cardiovascular risk.

Purpose of the Study:

  • To review antithrombotic therapy options for diabetic patients undergoing PCI.
  • To summarize current data on heparin, glycoprotein IIb/IIIa inhibitors, and oral antiplatelet agents in this population.

Main Methods:

  • Literature review of studies on antithrombotic agents in diabetic patients undergoing PCI.
  • Analysis of data on unfractionated heparin, low molecular weight heparin, intravenous glycoprotein IIb/IIIa blockers, and oral antiplatelet agents.

Main Results:

  • Antithrombotic therapies have enhanced PCI safety and effectiveness in diabetic patients.
  • Specific agents like heparins and glycoprotein IIb/IIIa blockers are crucial for managing thrombotic risk.
  • Oral antiplatelet agents play a key role in long-term management post-PCI.

Conclusions:

  • Effective antithrombotic strategies are vital for successful PCI in diabetic patients.
  • The choice of antithrombotic therapy should be tailored to individual patient risk profiles.
  • Continued research into optimal antithrombotic regimens for diabetics undergoing PCI is warranted.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...